Scarica l'app Stockscreener
17.18
1.55%
0.375
Precedente Chiudi:
$16.81
Aprire:
$17.05
Volume 24 ore:
752.10K
Relative Volume:
0.25
Capitalizzazione di mercato:
$1.07B
Reddito:
$16.10M
Utile/perdita netta:
$-198.97M
Rapporto P/E:
-4.9369
EPS:
-3.4809
Flusso di cassa netto:
$-183.99M
1 W Prestazione:
+10.99%
1M Prestazione:
+9.28%
6M Prestazione:
-70.57%
1 anno Prestazione:
+31.31%
Intervallo 1D:
$17.02
$17.63
Intervallo di 1 settimana:
$15.40
$18.20
Portata 52W:
$8.73
$71.50
Uniqure N V Stock (QURE) Company Profile
Nome
Uniqure N V
Settore
Industria
Telefono
1-339-970-7000
Indirizzo
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
17.18 | 1.05B | 16.10M | -198.97M | -183.99M | -3.4809 |
VRTX
Vertex Pharmaceuticals Inc
|
439.05 | 110.81B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
748.25 | 78.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
844.54 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
310.70 | 42.71B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
326.30 | 35.60B | 5.36B | 287.73M | 924.18M | 2.5229 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-11 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2026-03-09 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-03-09 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2026-03-03 | Downgrade | Mizuho | Outperform → Neutral |
| 2026-03-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2026-03-02 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2026-03-02 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-02-24 | Iniziato | Wolfe Research | Peer Perform |
| 2026-01-28 | Iniziato | Barclays | Equal Weight |
| 2025-11-04 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-08-14 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2025-04-01 | Ripresa | Chardan Capital Markets | Buy |
| 2024-12-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-02-29 | Downgrade | Goldman | Buy → Neutral |
| 2023-12-19 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-17 | Aggiornamento | UBS | Neutral → Buy |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-05-21 | Iniziato | UBS | Neutral |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-04-01 | Aggiornamento | Mizuho | Neutral → Buy |
| 2021-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-24 | Iniziato | H.C. Wainwright | Buy |
| 2020-11-11 | Iniziato | Berenberg | Buy |
| 2020-11-09 | Iniziato | Jefferies | Buy |
| 2020-11-04 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-08-25 | Iniziato | Raymond James | Strong Buy |
| 2020-07-31 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | Downgrade | Mizuho | Buy → Neutral |
| 2020-06-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | Iniziato | Cowen | Outperform |
| 2019-12-03 | Iniziato | Goldman | Buy |
| 2019-11-05 | Iniziato | Credit Suisse | Outperform |
| 2019-10-11 | Iniziato | Stifel | Buy |
| 2019-09-25 | Iniziato | Bernstein | Outperform |
| 2019-09-12 | Iniziato | Mizuho | Buy |
| 2019-07-30 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-07-08 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-04-12 | Iniziato | Piper Jaffray | Overweight |
| 2019-03-29 | Iniziato | Robert W. Baird | Outperform |
Mostra tutto
Uniqure N V Borsa (QURE) Ultime notizie
uniQure (Nasdaq: QURE) requests 12.4M-share delegation, 10% buyback - Stock Titan
(QURE) Risk Channels and Responsive Allocation - Stock Traders Daily
UniQure shares surge 26% on US FDA shakeup even as momentum tumbles: Will new leadership greenlight Huntington's therapy? - MSN
UniQure NV (NASDAQ:QURE) Q4 2025 earnings call transcript - MSN
uniQure (NASDAQ:QURE) Trading Down 3.7%Here's What Happened - MarketBeat
Early UniQure Fabry trial shows lasting enzyme boost, safety watch - MSN
UniQure used 'distorted comparison' in Huntington's asset trial: FDA official - MSN
UniQure surges following departure of key FDA official - MSN
uniQure (NASDAQ:QURE) Trading Up 10.9%Still a Buy? - MarketBeat
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 13, 2026 in uniQure N.V. Lawsuit – QURE - GlobeNewswire
QURE CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026 - Rutland Herald
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire Inc.
QURE UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026 - PR Newswire
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm - Morningstar
uniQure N.V. 24 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against uniQure N.V.QURE - ACCESS Newswire
QURE DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Reminds uniQure N.V. Investors to Join the Class Action Lawsuit Today - ACCESS Newswire
QURE Deadline: QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit - ChartMill
uniQure's Approval Process Hits a Roadblock—Savvy Investors Are Pulling Out Ahead of Further Declines - Bitget
Uniqure NV at TD Cowen Healthcare Conference Transcript - GuruFocus
Q4 2025 Uniqure NV Earnings Call Transcript - GuruFocus
uniQure Investors Face Deadline in Class Action Lawsuit - National Today
Barclays reaffirms equal weight rating for uniQure (QURE) - MSN
uniQure N.V. 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against uniQure N.V.QURE - Business Wire
QURE Deadline: Rosen Law Firm Urges uniQure N.V. (NASDAQ: QURE) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights - Bluefield Daily Telegraph
UNIQURE DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Encourages uniQure N.V. Stockholders ... - Bluefield Daily Telegraph
UNIQURE DEADLINE MONDAY: Bragar Eagel & Squire, P.C. - GlobeNewswire
uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock DeclineInvestors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC - ACCESS Newswire
Energy Moves: Will uniQure NV benefit from geopolitical trendsWeekly Trading Summary & Safe Entry Point Alerts - baoquankhu1.vn
uniQure N.V. (NASDAQ: QURE) Investor Alert: Deadline in Lawsuit on April 13, 2026 - openPR.com
QURE FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages uniQure N.V. Investors with Losses ... - Caledonian Record
QURE FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages - GlobeNewswire
QURE 4-DAY DEADLINE ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of "Distorted" Data - ChartMill
uniQure Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against uniQure N.V.QURE - ChartMill
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming DeadlinesQURE - PR Newswire
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
INVESTOR DEADLINE: uniQure (QURE) Investors with - GlobeNewswire
William Blair Downgrades uniQure N.V. (QURE) - MSN
QURE ALERT: Hagens Berman Updates uniQure (QURE) Probe After FDA Criticism, Lawsuit Filed; April 13 Deadline Nears - The Malaysian Reserve
QURE Stockholders Have Opportunity to Lead uniQure N.V. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
uniQure N.V. Securities Fraud Class Action Result of FDA - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines – QURE - ChartMill
QURE ALERT: Hagens Berman Updates uniQure (QURE) Probe After FDA - GuruFocus
FDA Criticizes uniQure's Gene Therapy, Lawsuit Filed - National Today
QURE Shareholder Alert: uniQure N.V. Securities Class Action Law - GuruFocus
UNIQURE N.V. (QURE) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds uniQure N.V. Investors of Upcoming Deadline - TMX Newsfile
QURE Shareholders Have Opportunity to Lead uniQure N.V. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
QURE Shareholder Alert: uniQure N.V. Securities Class Action Lawsuit Investors With Losses May Join — The Gross Law Firm - Morningstar
Press releases provided by CNW - Techaeris
Investors in uniQure N.V. Should Contact Levi & Korsinsky Before April 13, 2026 to Discuss Your Rights – QURE - GlobeNewswire
uniQure N.V. Faces Class Action Lawsuit Deadline - National Today
Bronstein, Gewirtz & Grossman LLC Urges uniQure N.V. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
Uniqure N V Azioni (QURE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Uniqure N V Azioni (QURE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Abi-Saab Walid | Chief Medical Officer |
Mar 04 '26 |
Sale |
9.06 |
808 |
7,320 |
189,669 |
| Potts Jeannette | Chief Legal Officer |
Mar 04 '26 |
Sale |
9.06 |
3,412 |
30,913 |
138,483 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Mar 04 '26 |
Sale |
9.06 |
12,000 |
108,720 |
226,581 |
0.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):